Paris, France

Andrees Boehme

This inventor holds 1 USPTO granted patent. Top assignees: Sanofi-A Ventis Deutschland Gmbh, University of Ulster. Active years: 2016.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Andrees Boehme: Innovator in Neurodegenerative Disease Treatment

Introduction

Andrees Boehme is a notable inventor based in Paris, France. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of neurodegenerative diseases. His innovative work has led to the development of a unique pharmaceutical composition aimed at improving patient outcomes.

Latest Patents

Andrees Boehme holds a patent for a pharmaceutical composition designed for the prevention and treatment of neurodegenerative diseases. The composition includes desProExendin-4(1-39)-Lys-NHor and a pharmaceutically acceptable salt, along with optional carriers or adjuvants. This patent highlights his commitment to advancing medical science and addressing critical health challenges.

Career Highlights

Throughout his career, Andrees has worked with prominent organizations, including Sanofi-Aventis Deutschland GmbH and the University of Ulster. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Andrees Boehme has collaborated with notable colleagues such as Sibylle Hess and Christian Hoelscher. These partnerships have further enriched his research and development efforts in the pharmaceutical industry.

Conclusion

Andrees Boehme's contributions to the treatment of neurodegenerative diseases through his innovative pharmaceutical compositions demonstrate his dedication to improving healthcare. His work continues to inspire advancements in medical research and patient care.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…